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SARS-CoV-2
Elena Cabezón and Ignacio Arechaga*
Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Universidad de Cantabria-CSIC, Santander, Spain
The current outbreak of SARS-CoV-2 virus has caused a large increase in mortality
and morbidity associated with respiratory diseases. Huge efforts are currently ongoing
to develop a vaccine against this virus. However, alternative approaches could be
considered in the fight against this disease. Among other strategies, structural-based
drug design could be an effective approach to generate specific molecules against
SARS-CoV-2, thus reducing viral burden in infected patients. Here, in addition to
this structural approach, we also revise several therapeutic strategies to fight against
this viral threat. Furthermore, we report ACE-2 genetic polymorphic variants affecting
residues involved in close contacts with SARS-CoV-2 that might be associated to
different infection risks. These analyses could provide valuable information to predict
the course of the disease.
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INTRODUCTION
Severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome
coronavirus (MERS-CoV) have been responsible for major outbreaks, causing the death of
hundreds of patients (Ksiazek et al., 2003; Kuiken et al., 2003; Rota et al., 2003; Anderson et al., 2004;
Assiri et al., 2013; De Wit et al., 2016; Song et al., 2019). The current pandemic spread of SARS-CoV-
2 virus, responsible for the coronavirus disease 2019 (Covid-19), has driven health systems around
the world to the edge of collapse. Covid-19 has a lower lethality rate than SARS and MERS, which
emerged in 2002 and 2012, respectively. However, and precisely because of its lower fatality, SARS-
CoV-2 virus has widely spread around the world. The rate of infection by this virus is superior to
other common respiratory viruses, such as influenza, with a larger basic reproductive number (Ro),
and a higher case fatality rate (CFR). Nonetheless, it is not possible to know exactly the infective and
fatality rate numbers, as it is very likely that there are many undetected, infected people. What is
certain is that the world is in a state of emergency in the fight against this disease. Several initiatives
are currently on the way with special focus on development of vaccines to protect populations
against this infection.
Vaccines are the main tool to prevent the spread of the infection in the long term. Unfortunately,
they have little impact in patients already infected with the virus. Therefore, therapeutic drugs
should be found to treat infected patients at hospitals. Several drugs are under consideration to
deal with the disease, although most of them have not been specifically designed to target this virus.
In the battery of available therapeutic drugs we can find antivirals, such as remdesivir, lopinavir,
ritonavir, ribavirin, and fapiravir. Molecules affecting interactions of SARS-CoV-2 with different
cell partners are also being used in clinical setups, albeit with no clear benefits. Some examples
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are the anti-paludic chloroquine (Colson et al., 2020; Gao
et al., 2020) and its derivative hydroxy-chloroquine (Liu et al.,
2020) combined with azithromycin (Gautret et al., 2020), a
broad-spectrum antibiotic. However, several studies question the
effectiveness of chloroquine, and articles on this matter have
been retracted (Mehra et al., 2020a,b). Recently, the WHO has
recommended against the use of high doses of chloroquine for
treatment of Covid-19.
A recent high-throughput mass spectrometry analysis found
that SARS-CoV-2 interacts with multiple cellular systems
(DNA replication, host translation machinery, RNA processing
and replication, innate immune system pathways, vesicle
trafficking, lipid modification, nuclear transport, mitochondria,
etc.) (Gordon et al., 2020). Therefore, instead of trying to develop
new drugs, some trials are underway to test compounds already
approved for human use, in the hope of finding one that might
affect those interactions. This strategy would try to stop the cell
from making new viral particles out of viral RNA, thus preventing
virus translation (Gordon et al., 2020). However, most of the
efforts are focused on the viral spike protein that SARS-CoV-
2 uses to infect cells, in a strategy that seeks to disrupt the
virus entry. SARS-CoV-2 binds to the angiotensin conferring
enzyme receptor (ACE-2) with high affinity, via the spike protein
(Hoffmann et al., 2020; Wrapp et al., 2020). Therefore, the use of
antibodies to neutralize the binding of the virus to ACE-2 has also
been considered in the treatment of the disease (Kruse, 2020), as
well as the use of peptides that mimic the interaction between the
virus and ACE-2. Thus, molecules that could prevent the binding
of the virus to ACE-2 would be of great interest to treat this
disease. Here, we describe in detail the interactions between SAR-
CoV-2 and ACE-2, and the main therapeutic strategies that are in
consideration for the treatment of Covid-19 to inhibit virus entry
or virus translation, but with a particular emphasis on the viral
spike protein, since most of the efforts are focused on this target.
CORONAVIRUS STRUCTURE
Coronaviridae is a family comprising several viral species (Lai
et al., 2007; Adams and Carstens, 2012), seven of which are able
to infect human cells (the alphacoronavirus HCoV-229E, HCoV-
NL63, and the betacoronavirus HCoV-OC43, HCoV-HKU1,
SARS-CoV, MERS-CoV, and SARS-CoV-2) (Kin et al., 2015; Su
et al., 2016). These pleomorphic membrane-enveloped viruses
consist of a positive sense RNA molecule and four essential
structural proteins: M (the most abundant glycoprotein in the
membrane), E (an envelope small membrane protein), N (a
nucleocapsid protein), and S (the spike protein, which is also
a membrane glycoprotein) (Figure 1). The spike glycoproteins
(S) form homotrimers that decorate the viruses (Du et al., 2009;
Kirchdoerfer et al., 2016; Walls et al., 2016; Wrapp et al., 2020;
Yan et al., 2020). The spike protein is essential for binding
the receptor and for its entry into the infected cell (Gallagher
and Buchmeier, 2001; Bosch et al., 2003; Li et al., 2006).
During the course of infection the S protein is cleaved by host
proteases in two fragments, the S1 and S2 subunits, which
remain non-covalently bound in the prefusion conformation
(Bosch et al., 2003; Belouzard et al., 2009; Millet and Whittaker,
2014; Walls et al., 2020). The S1 subunit contains a Receptor
Binding Domain (RBD) which interacts with the cell receptor
(Babcock et al., 2004; Li, 2015), whereas the S2 subunit acts in
the fusion and entry into the cell (Walls et al., 2020). The S2
subunit is a multidomain protein consisting of a cytoplasmic
domain, a transmembrane span, a fusion peptide, and two heptad
repeats (HR1 and HR2) (Bosch et al., 2004; Liu et al., 2004; Xia
et al., 2020b). These two heptad repeats oligomerize into a six-
helix bundle fusion core, which is essential for viral integrity and
infectivity. There has been much effort in developing peptides
based on HR1 and HR2 structures to prevent infection by these
viruses, mainly for MERS-CoV and HCoV-229E, with promising
results (Gao et al., 2013; Lu et al., 2014; Sun et al., 2017; Xia
et al., 2018). However, the entry pathway of MERS-CoV into the
cell, mediated by the DPP4 receptor (Meyerholz et al., 2016), is
different from that used by both SARS viruses, SARS-CoV and
SARS-CoV-2, which bind to the ACE-2 receptor. Therefore, these
peptides may be helpless in the current outbreak.
INTERACTIONS OF THE SPIKE PROTEIN
WITH THE ACE-2 RECEPTOR
The spike S1 glycoprotein of SARS like viruses interacts
very strongly with ACE-2, a protein receptor involved in the
maturation of angiotensin, an essential peptide in vascular
homeostasis (Donoghue et al., 2000; Crackower et al., 2002).
ACE-2 receptor is a membrane protein, consisting of an
N-terminal domain, named PD, and a C-terminal Collectrin-
like domain (CLD) (Zhang et al., 2001). Structures of the ACE-2
PD domain in complex with SARS-CoV receptor domain (RBD)
have been published (Li et al., 2005, PDB id: 2AJF). Recently, the
atomic structure of the spike glycoprotein of SARS-CoV-2 has
been determined (Wrapp et al., 2020, PDB id: 6VSB; Walls et al.,
2020, PDB id: 6VXX and 6VYB; Supplementary Figure S1).
Moreover, the structure of the complex formed between the RBD
of the viral spike and ACE-2 receptor has also been solved (Shang
et al., 2020b, PDB id: 6VW1; Yan et al., 2020, PDB id: 6M17 and
6M18; Wang Q. et al., 2020, PDB id: 6LZG; Figure 2). Despite
the high degree of homology shared by the spike glycoproteins
of SARS-CoV and SARS-CoV-2 viruses, monoclonal antibodies
directed against the SARS-CoV of 2002/3 virus were not effective
against the new SARS, revealing important differences between
the two spike viral proteins (Wrapp et al., 2020).
Sequence comparison between the SARS-CoV and SARS-
CoV-2 spike proteins revealed 76% identity (Supplementary
Figure S2). The main sequence variations are precisely in the
RBD domain involved in ACE-2 interaction. Although the
interface between ACE-2 and SARS-CoV-2 (Yan et al., 2020) is
similar to that of ACE-2 with SARS-CoV (Li et al., 2005), a
close inspection of this area reveals some important differences
(Wang Y. et al., 2020). Among these, substitutions of Asn479
and Thr487 in SARS-CoV for Gln493 and Asn501 in SARS-
CoV-2, respectively, seem to be particularly relevant, as they
are key residues in the interaction with the ACE-2 receptor.
Up to six other modifications in SARS-CoV-2 are present in
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FIGURE 1 | Schematic representation of SARS-CoV-2 genome and spike functional domains. (A) SARS-CoV-2 single stranded positive RNA contains two large
ORF genes that encode 16 non-structural proteins, and four genes that encode four essential structural proteins: the spike (S), the envelope (E), the membrane (M),
and the nucleocapsid (N). In addition, the genome contains a number of accessory genes (3a, 6, 7a, 7b, and 8). (B) The spike gene encodes two spike subunits, S1
and S2. The cleavage site between S1 and S2 is indicated with an arrow. The S1 subunit contains a domain (RBD, receptor binding domain) close to the
C-terminus, which recognizes and binds the angiotensin-II conferring enzyme receptor (ACE-2). Fusion and entry of the virus into the receptor cell is mediated by the
S2 subunit, which contains a fusion protein (FP) and two heptad repeat motifs (HR1 and HR2). For comparison, image follows the schematic representation for
SARS-CoV in Song et al. (2019).
FIGURE 2 | Structural comparison of SARS-CoV and SARS-CoV-2 spike
proteins in complex with the ACE-2 receptor. (A) protomer superposition of
SARS-CoV (blue) and SARS-CoV-2 (pink). (B) structures of the complex
formed by the RBD of SARS-CoV (blue) and ACE-2 (light green) (PDB id: 2ajf;
Li et al., 2005), and the RBD of SARS-CoV-2 (pink) and ACE-2 (dark green)
(PDB id: 6vw1, Shang et al., 2020a; PDB id: 6m17, Yan et al., 2020; PDB id:
6lzg, Wang Q. et al., 2020), respectively, have been aligned and
superimposed using UCSF Chimera (Pettersen et al., 2004).
this region (Arg426→Asn439, Tyr442→Leu455, Leu443→Phe456,
Phe460→Tyr473, Leu472→Phe486, and Tyr484→Gln498; SARS-
CoV→SARS-CoV-2 mutations) (Supplementary Figure S3). In
addition to these substitutions, it is worth noting the change of
Val404 in SARS-CoV for Lys417 in SARS-CoV-2 (Figure 3). The
introduction of a positive charge in this position contributes to
the formation of a salt bridge with residue Asp30 in ACE-2 (Yan
et al., 2020). Likewise, the change of Leu472 for Phe486 seems to
favor the formation of strong Van der Waals interactions with
Met82 in the receptor (Yan et al., 2020). Other residues in this
region of interaction between SARS-CoV and SARS-CoV-2 with
ACE-2 are well conserved. Overall, these modifications seem to
increase the stability of the complex formed between the RBD of
SARS-CoV-2 and ACE-2 receptor, which is in agrement with the
FIGURE 3 | Interacting region between SARS-CoV-2 and ACE2.
(A) Structures of the RBDs of both SARS-CoV (slate blue) and SARS-CoV-2
(pink) in complex with ACE-2 receptor (green). (B) amino-acid residues of
SARS-CoV-2 RBD domain (pink) interacting with the N-terminus and C-end of
the α1-helix of ACE-2 receptor (green). Equivalent positions in SARS-CoV
(2002/3) are shown (light blue). (C), the main differences between both spike
viral proteins are the substitution of Val404 for Lys417, which favors the polar
interaction with Asp30 of ACE-2, and the substitution of Leu472 for Phe486,
which enables the formation of Van der Waals bonds with Met82 and
hydrophobic interactions with Tyr83.
high affinity (Kd = 15 nM) reported for the binding between both
proteins (Wrapp et al., 2020). This extraordinary affinity could
explain the high rates of infection observed in Covid-19.
A recent analysis of 5,349 SARS-CoV-2 genomes (Phelan
et al., 2020) has found numerous SNPs (Single Nucleotide
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Polymorphisms), although at low frequencies. Only three
mutations are more prevalent, two mutations in the nucleocapsid
protein and one in the spike protein (D614G). This D614G
mutation has been suggested to increase the morbility and
mortality of the disease (Eaaswarkhanth et al., 2020; Korber et al.,
2020). In any case, despite this mutation, the spike protein is
relatively stable, which is good news for the development of
vaccines. Nonetheless, a close inspection of further mutations is
paramount in order to prevent failures in the design of a vaccine.
Finally, another point to consider is the glycosylation of the
spike protein, since it could facilitate the hiding of specific
epitopes, which in turn would neutralize antibody recognition
by the immune system. Glycosylation has been described for a
number of coronaviruses (Walls et al., 2019; Yang et al., 2020).
A recent site-specific mass spectrometry analysis (Watanabe
et al., 2020) has enabled mapping of the glycosylation sites on
the viral SARS-CoV-2 spike. These viral glycans were found
to be different from typical host glycans. They are mainly
oligomannosides and complex fucoside-derived sugars localized
in 22 different sites on the spike protein (Watanabe et al.,
2020). It is not clear yet how this glycosylation pattern affects
the interaction with the ACE-2 receptor but this type of study
could provide a framework to develop future glycoprotein-
based vaccines.
ACE-2 GENETIC VARIANTS THAT MIGHT
BE ASSOCIATED WITH A DIFFERENT
RISK FOR COVID-19 OUTCOME
Recently, it has been shown that ACE-2 expression levels may
be critical for the susceptibility and outcome of Covid-19 (Cao
Y. et al., 2020). In a systematic analysis of ACE-2 coding-region
variants and expression quantitative trait loci (eQTL) variants,
the authors found that East Asian populations have increased
allele frequencies in the eQTL variants associated with high
ACE-2 expression, suggesting an enlarged susceptibility to SARS-
CoV and SARS-CoV-2 infection. However, no clear evidence of
resistant mutations for coronavirus spike-protein binding was
detected (ChinaMAP and 1KGP databases). In this context, a
genetic analysis for coding variants affecting ACE-2 expression
is of particular interest, since ACE2 gene polymorphisms and
ACE2 mRNA expression might influence the disease outcome
(Devaux et al., 2020).
Genetic variants in the ACE-2 receptor affecting the
interaction with the spike protein might be associated with
a different risk of SARS-CoV-2 infection. The ACE-2 gene is
associated with 6634 variant alleles (Ensembl GRCh38.p13), and
three of them are missense variants that affect three essential
residues involved in close contacts between the RBD of the
spike protein and the ACE-2 receptor (Table 1). The missense
variants E37K and E329G would affect H-bonds and essential
polar contacts with residues of the spike protein, whereas M82I
variant could have a bearing on the van der Waals interactions
established with a leucine or a phenylalanine in SARS-CoV
and SARS-CoV-2 viruses, respectively. In particular, molecular
modelling of E329G variant showed noticeable variations in the
interactions with the viral spike protein (Hussain et al., 2020).
Although these are very low-frequency missense variants, found
in the gnomAD database (MAF < 0.01), it might be interesting
to investigate whether they are associated with a lower risk of
infection, corresponding to that percentage of the population that
shows very weak symptoms or are practically asymptomatic.
The ACE-2 receptor forms a dimer, which can fluctuate
between two conformations, “open” and “closed” (Towler et al.,
2004; Yan et al., 2020). However, when ACE-2 is bound to the
RBD of the spike protein, only the closed state is present, which
suggests that residues stabilizing the dimer interface might be
also essential for virus infection. Table 2 shows genetic variants
in the ACE-2 receptor affecting essential residues involved in
dimerization. Missense variants affecting this interface might also
be associated to a lower risk of SARS-CoV-2 infection.
In addition, recent studies on the biology of viral infection
also indicate that there might be a sex predisposition to develop
Covid-19, with men more prone to being infected (Cai, 2020;
Ciaglia et al., 2020; Guan et al., 2020). It is worth noting that
the ACE-2 gene is located on the X chromosome and, therefore,
allele variants associated to an increased risk of infection would
affect women and men differently. As ACE-2 genetic variants
are at different frequencies in the general population, it might
be worthwhile investigating whether they confer a genetic
predisposition for a different risk of infection. This knowledge
would be of great interest to improve disease management,




Antibodies that recognize the epitope domain of previous SARS-
CoV have been reported (Sui et al., 2004; Ter Meulen et al.,
2004; Qiu et al., 2005; van den Brink et al., 2005), as well
as monoclonal antibodies (m396 and S230.15) that neutralize
SARS-CoV/ACE2 interaction (Zhu et al., 2007). Some of these
antibodies (m396) bind to the RBD of the viral spike with high
affinity (Prabakaran et al., 2006), thus preventing the binding of
the virus to ACE-2. Unfortunately, none of these antibodies were
able to recognize SARS-CoV-2 (Wrapp et al., 2020). Therefore,
production of specific monoclonal antibodies against SARS-CoV-
2 should be a priority. A cryptic epitope highly conserved in
the RBD of SARS-CoV and SARS-CoV-2 has been identified
(Yuan et al., 2020) and antibodies (CR3022) directed against
it have been shown to bind with high affinity in vitro (Tian
et al., 2020). Generation of antibodies by phage display could
also be an alternative strategy. In that sense, antibodies already
developed against HR1 and HR2 domains of the S2 spike of
SARS-CoV (Elshabrawy et al., 2012) and other viruses (Shin et al.,
2019) could provide leads to generate specific antibodies against
SARS-CoV-2. However, more research is needed before it can
be translated to clinical practice. Other alternative approaches,
such as purifying polyclonal antibodies from animals, do not
look promising. Passive immunotherapy with antibodies from
plasma of already infected people might be an alternative
therapy (Walker and Burton, 2018). Unfortunately, the variability
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TABLE 1 | ACE-2 missense variants affecting residues involved in SARS-CoV and SARS-CoV-2 spike-protein binding.
ACE-2 variant Polymorphism Allele frequency* Codons SARS-CoV interaction SARS-CoV-2 interaction
E37K rs146676783 9.1 × 10−5 GAA/AAA Y491 Y505
M82I rs766996587 1.4 × 10−4 ATG/ATT/ATA L472 F484
E329G rs143936283 9.1 × 10−5 GAA/GGA R426 N439
*Source: Genome aggregation database (gnomAD database).
TABLE 2 | ACE-2 missense variants affecting residues involved in ACE-2 dimerization.
ACE-2 variant polymorphism Allele frequency* Codons ACE-2 dimer interaction
N638S rs183135788 1.8 × 10−4 AAT/AGT R652, Q653
S709R rs1052746182 2.8 × 10−5 AGC/CGC R716
R710H rs370187012 4.6 × 10−5 CGT/CAT N636
R710C rs901495523 9.2 × 10−5 CGT/TGT N636
R716H rs200540199 1.4 × 10−4 CGT/CAT S709,D713
R716C rs144869363 2.8 × 10−5 CGT/TGT S709,D713
*Source: Genome aggregation database (gnomAD database).
in plasma samples and viral cargo of previously infected
people makes this approach less precise and reproducible.
Another clinical trial for the treatment of Covid-19 is based on
Tocilizumab, a humanized monoclonal antibody commercialized
by Roche to treat rheumatoid arthritis, which is being used in
Covid-19 infected patients with promising results (Fu et al., 2020;
Guo et al., 2020).
Novel strategies that rely on targeting the viral receptor
protein in the cell surface, preventing the binding and entry of
the virus inside the cell, could be more promising. For instance,
fusions of immunoglobulin Fc with a soluble fraction of ACE-
2 has been proposed to prevent the binding of the virus to the
receptor (Kruse, 2020). As additional benefit, this therapy would
supplement ACE-2 levels during infection, and it would boost the
immune system to generate lasting immunity (Kruse, 2020).
Another strategy has been to generate fusion proteins
containing the extracellular domain of human ACE2 and the Fc
region of the human immunoglobulin IgG1 to neutralize SARS-
CoV or SARS-CoV-2 spike proteins in vitro (Lei et al., 2020). As
the authors state, these fusion proteins have potential applications
in the diagnosis, prophylaxis, and treatment of SARS-CoV-2.
Peptides That Prevent Interactions
Between ACE-2 and SARS-CoV-2
In addition to the generation of antibodies, treatment with
antiviral peptides could provide an alternative route of therapy
to avoid virus entry. In contrast to small inhibiting molecules,
peptides have the advantage of disrupting relatively large protein-
protein interfaces. Antiviral peptides were designed against
MERS-CoV (Gao et al., 2013; Lu et al., 2014; Sun et al., 2017) and
also against SARS-CoV virus in order to disrupt the interaction
between the spike protein and the ACE-2 receptor (Hu et al.,
2005) or affect the interface of the spike trimer (Zheng et al.,
2005). Peptides selected against the S2 spike subunit (Yuan et al.,
2004; Xia et al., 2018) and peptides including short sequences of
the RBD of SARS-CoV were also proposed (Struck et al., 2012).
Recently, and based on the pan-coronavirus virus fusion inhibitor
EK1, developed for SARS-CoV and MERS-CoV (Xia et al., 2019),
other lipopeptides, such as EK1C4, have been produced (Xia et al.,
2020a), which could be effective in the treatment of Covid-19.
Close inspection of the amino acid substitutions in the
interacting region between SARS-CoV-2 spike protein and ACE-
2 receptor provides a framework to generate a library of antigenic
peptides. These peptides should block the interaction of the
virus with target cells. To this respect, some reports have been
recently published in which peptides specifically designed to bind
SARS-CoV-2 spike protein have been generated (Zhang et al.,
2020). These peptides should be able to disrupt SARS-CoV-2
RBD-ACE2 interface. One of these peptides, named SBP1, is a 23-
mer molecule including amino acid residues 21–43 from ACE-2
α1-helix (IEEQAKTFLDKFNHEAEDLFYQS) (Supplementary
Figure S4). This peptide is able to bind the RBD of SARS-CoV-2
at nanomolar levels (Zhang et al., 2020), but it is unknown if this
peptide is tolerated by the immune system.
Interestingly, another short region in ACE-2 involved in
closed contacts with the spike can be appreciated (residues 325–
354) (Supplementary Figure S3), which could be a lead to
develop other effective peptides. The affinity or stability of such
a putative peptide has not been assayed, but it might be worth
testing it, alone or in combination with other peptides.
The use of a soluble fraction of ACE-2, instead of small
peptides, to snatch viral particles has been suggested (Batlle et al.,
2020). Such soluble ACE-2 recombinant protein has already been
used in the treatment of angiotensin II-dependent hypertension
(Wysocki et al., 2010), but its potential use in the treatment of
Covid-19 is unknown.
Specific Proteases
Another therapeutic alternative is the use of specific proteases.
The spike protein of previous SARS-CoV is cleaved by a host
transmembrane Type II serine protease TMPRSS2 (Glowacka
et al., 2011; Reinke et al., 2017). This cleavage results in the
activation of the spike protein, which, in turn, facilitates the entry
of the virus into the cell. Thus, development of therapeutic drugs
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targeting this protein could also open an alternative route in the
treatment of patients (Simmons et al., 2011). In this regard, some
serine protease inhibitors targeting TMPRSS2 were proposed
(Kawase et al., 2012; Zhou et al., 2015). Recently, it has been
shown that SARS-CoV-2 entry into the cells is also mediated
not only by ACE-2 but also by TMPRSS2 (Hoffmann et al.,
2020). Moreover, this entry is blocked by camostate mesylate, a
TMPRSS2 serine protease inhibitor, which makes this molecule a
potential drug to be used in clinical trials (Hoffmann et al., 2020).
Endosomal cysteine proteases, like cathepsin B and L (CatB/L),
might also be inhibited with compounds such as E64 (Hoffmann
et al., 2020). Interestingly, these authors also found that sera
from patients infected with SARS-CoV neutralized SARS-CoV-2
entry into the cell.
In silico analyses of putative protease SARS-CoV-2 inhibitors
are being used to identify potential therapeutic compounds
(Pant et al., 2020). Among the potential inhibitors found in
this analysis, there are some already described antivirals, such
as lopinavir and ritonavir, and other FDA approved drugs, like
cobicistat and darunavir.
Furin-Like Enzymes
Binding and release of viral particles is activated by specific
cellular proprotein convertases, such as furin, trypsin, and
cathepsin-L (Seidah and Prat, 2012; Millet and Whittaker, 2015;
Izaguirre, 2019). Therefore, development of drugs that target
the furin-like process mechanisms constitutes another avenue of
research. For instance, teicoplanin, an antibiotic used to treat
Staphylococcus infection, has been found to inhibit cathepsin-
L in several coronavirus, including SARS-CoV-2 (Baron et al.,
2020). Based on the crystal structure of furin, several inhibitors,
like 2,5-dideoxystreptamine-mediated inhibitor, were previously
described and tested in clinical trials against SARS-CoV (Dahms
et al., 2017). This drug is now a promising candidate for Covid-
19 treatment. Some cell furin-like proteases are able to target
the spike protein of several coronavirus species, including SARS-
CoV-2 (Coutard et al., 2020). Interestingly, the furin cleavage site
in SARS-CoV-2 site differs from that present in other coronavirus
(Coutard et al., 2020). However, as furin-like molecules are
involved in multiple metabolic pathways, any drug targeting these
molecules might have serious adverse effects.
Antivirals
Various essential stages in the viral life cycle, such as RNA
synthesis, are susceptible to be targeted by drugs. In that
sense, several antivirals are being used in the treatment of
patients affected by Covid-19 (Table 3). Among them we
can find adenosine nucleotide analogs, such as remdesivir, a
broad spectrum antiviral agent with activity against a number
of different virus, including Ebola virus (Siegel et al., 2017;
Tchesnokov et al., 2019) and pathogenic coronavirus SARS-CoV
and MERS-CoV (De Wit et al., 2016). Remdesivir inhibits viral
RNA polymerase, thus reducing viral load. Remdesivir has been
approved by the FDA to be used in the treatment of patients
infected with SARS-CoV-2, since compassionate treatment with
remdesivir has been reported to improve the outcome in several
patients (Grein et al., 2020). Combined treatment of remdesivir
with chloroquine has also been suggested to inhibit SARS-CoV-2
(Wang Y. et al., 2020). Other tested antivirals such as lopinavir,
an HIV-1 protease inhibitor which, combined with ritonavir, was
used against SARS and MERS (Chu et al., 2004; Chan et al., 2015)
has also been tried with Covid-19 patients (Cao B. et al., 2020).
Ribavirin, a nucleoside analog developed against influenza and
hepatitis C virus (Feld and Hoofnagle, 2005; Te et al., 2007),
has also being used in animal models infected with MERS in
combination with interferons (IFNs) (Al-Tawfiq et al., 2014),
but its use against respiratory diseases could not be advisable,
as it reduces hemoglobin concentration (Sheahan et al., 2020).
A combination therapy with lopinavir, ritonavir, ribavirin, and
interferon a has been proposed as treatment of MERS-CoV
infections (Kim et al., 2015). Favipiravir, an RNA dependent RNA
polymerase (RdRp) inhibitor (Furuta et al., 2013), has been used
against Ebola and Marburg virus (Bixler et al., 2018), influenza
(Goldhill et al., 2018), and many other RNA viruses.
However, none of these antivirals were specifically designed
against SARS-CoV-2. Therefore, development of specific
antivirals against SARS-CoV-2 is a foremost objective.
Other Potential Therapeutic Treatments
An alternative strategy could be the use of small interfering
RNA (siRNA) to target directly the viral RNA (Qureshi et al.,
2018). However, administration of these molecules to the patients
presents practical problems. A similar approach was tried against
Ebola and, despite of initial success in preclinical animal tests (Thi
et al., 2015), it failed in clinical trials.
Another approach could be to target viral assembly. The
formation of the S spike trimer might not be a fast and direct
process, so there is a chance to block the quaternary structure
of the spike (Bongini et al., 2020). Analysis of protein-protein
interfaces of the spike has led to the prediction of ligands
(Ergoloid, Darifenacin, 5-methyl-tetrahydrofolic acid, Buclizine,
Saquinavir, Solifenacin, Sorafenib, tetrahydrofolic acid) that
potentially could affect this process (Bongini et al., 2020).
In addition to the generation of specific peptides directed
to neutralize SARS-CoV-2 spike or the action of the serine
protease TMPRSS2 already mentioned in the previous section,
other targets, such as the viral non-structural proteins (nsp) or
the accessory proteins (envelope, nucleocapsid, and membrane)
could be considered. Coronavirus nsps are relatively well
conserved (Totura and Bavari, 2019; Kim et al., 2020). Among
these, 3C-like protease (3CLpro), papain-like protease (PLpro),
and RNA-dependent RNA polymerase (RdRp) have been
suggested to be targets for antiviral drug discovery (Totura and
Bavari, 2019). In contrast to the structural and nsp proteins,
amino acid conservation in accessory proteins is low, which
makes them unsuitable drug targets.
A recent mass spectrometry analysis identified 332 putative
human targets for therapeutical drugs (Gordon et al., 2020).
Screening of over 60 potential leads resulted in two classes
of molecules that reduced effectively viral infectivity. These
molecules were protein biogenesis inhibitors (zotatifin, ternatin-
4, and PS3061) and ligands of Sigma1 and Sigma2 receptors
(haloperidol, PB28, PD-144418, and hydroxychloroquine)
(Gordon et al., 2020). In addition, clemastine, cloperastine,
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TABLE 3 | Drugs proposed for the treatment of SARS-CoV-2 infected patients.
Drug Target Virus References
80R scFv mAb spike SARS-CoV Sui et al., 2004





spike SARS-CoV van den Brink et al., 2005
CR3009 mAb
CR3018 mAb
N SARS-CoV van den Brink et al., 2005





Zhu et al., 2007
ACE2-Fc/IgG spike SARS-CoV-2 Kruse, 2020; Lei et al., 2020
HR1-1, HR2-18 spike SARS-CoV Yuan et al., 2004
438YKYRYL443 spike SARS-CoV Struck et al., 2012
229E-HR1P 229E-HR2P spike SARS-CoV Xia et al., 2018
Cobicistat, Darunavir spike SARS-CoV-2 Pant et al., 2020
EK1 spike SARS-MERS Xia et al., 2019
EK1C4 spike SARS-CoV-2 Xia et al., 2020a
Ergoloid, Darifenacin,
5MTH-folic acid, Buclizine, Saquinavir, Solifenacin,
Sorafenib
spike SARS-CoV-2 Bongini et al., 2020
Camostate mesylate TMPRSS2 SARS-CoV
SARS-CoV-2
Kawase et al., 2012; Hoffmann et al., 2020
E64d CatB/P13pc SARS-CoV
SARS-CoV-2
Kawase et al., 2012; Hoffmann et al., 2020
Glycyrhizin, Aescin Reserpine 3CLpro SARS-CoV Wu et al., 2004
Teicoplanin CatB/P13pc SARS-CoV-2 Baron et al., 2020
DDOS inhibitor Furin SARS-CoV Dahms et al., 2017
Remdesivir viral RNA polymerase Ebola Siegel et al., 2017; Tchesnokov et al., 2019






Chu et al., 2004; Wu et al., 2004; Chan et al.,







Feld and Hoofnagle, 2005; Te et al., 2007;
Al-Tawfiq et al., 2014; Sheahan et al., 2020;




Furuta et al., 2013; Bixler et al., 2018; Goldhill
et al., 2018; Wang M. et al., 2020




SARS-CoV-2 Gordon et al., 2020
Tocilizumab IL6 receptors SARS-CoV-2 Fu et al., 2020; Guo et al., 2020
chloroquine
Hydroxy-chloroquine
SARS-CoV-2 Colson et al., 2020; Gao et al., 2020; Gautret
et al., 2020; Liu et al., 2020; Mehra et al., 2020b
Compounds affecting the entry of the virus into human cells include antibodies (light yellow), small peptides and drugs disrupting binding to the ACE-2 receptor (dark
yellow), and specific proteases (salmon). Strategies affecting virus translation involve furin-like enzymes (pink), antivirals (light blue), and other inhibitors affecting essential
proteins and cell functions (light green). Chloroquine and derivatives (red), although initially proposed as potential drugs to treat SARS-CoV-2, have been lately dismissed.
siramesine, zotatifin, and progesterone were also identified as
potential drugs in this study.
OUTLOOK
Much effort is currently ongoing to find a specific vaccine to
protect populations against the threat of SARS-CoV-2. However,
the development of a new vaccine is a long process that will
come too late for hundreds of thousands of already infected
people. Antiviral therapeutics such as remdesivir, lopinavir,
ritonavir, favipiravir, or hydroxy-chloroquine, combined with
immunotherapy, could work, and some of them are being used
in the front line against the disease. However, new drugs that
target specifically the new virus are needed to increase our
weaponry in the fight of this pandemic emergency. To this end,
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small peptides containing the sequence of the ACE receptor
directly involved in SARS-CoV-2 binding might be a promising
alternative in the fight against this pandemic emergency. The
detailed analysis of ACE-2 spike viral protein interactions carried
out in this work suggests putative peptides that might fulfill this
requirement, as well as certain ACE2 genetic variants that might
be associated with a lower risk of infection. These molecules,
combined with panviral strategies and drugs targeting other
mechanisms of viral infection, could provide effective therapies
for the management of the disease.
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